HCW Biologics reports $1.6 million private securities sale in SEC filing

HCW Biologics Inc. filed a Form D with the SEC on August 6, 2026, disclosing an exempt securities offering. The filing marks a new notice, with a date of first sale listed as 2026-07-29.¹

The company reported a total offering amount of $1,600,000, with the total amount sold also at $1,600,000 and nothing remaining to be sold.¹ The total number of investors who had already invested in the offering was listed as four.¹

The offering relied on Rule 506(b) as its claimed federal exemption.¹ HCW Biologics stated that the offering was not tied to a merger, acquisition, or similar deal, as the filing's item on whether the offering was made in connection with what the form calls a "business combination transaction, such as a merger, acquisition or exchange offer" was answered no.

The securities offered included equity, along with an option, warrant or other right to acquire another security, and a security to be acquired upon exercise of such an option, warrant or right.¹ The company reported no sales commissions or finders' fees connected to the offering, and no proceeds allocated to payments for named executive officers, directors, or promoters.

The filing lists Hing C. Wong, Rebecca Byam, Peter Rhode, and Lee Flowers as executive officers, with Wong also serving as a director alongside directors Scott T. Garrett, Rick S. Greene, and Lisa M. Giles.¹ The company is classified under the biotechnology industry group within health care.¹ Rebecca Byam, identified as Chief Financial Officer, signed the notice on August 6, 2026.